# Major Recall Alert: Atropine Sulfate Ophthalmic Solutions and Other Aved Products Recalled Due to Products Sold Without Market Authorization (DIN) in Canada
In a significant public health announcement, Health Canada has issued a recall for several ophthalmic products produced by Labtician Ophthalmics, Inc. under the Aved brand. These products were sold without proper market authorization (Drug Identification Number, or DIN) in Canada due to third-party branding concerns. This recall could impact individuals relying on these medications for various eye and vision-related conditions. It is crucial to understand the risks, check your medications, and ensure your health and safety.
## Why This Recall is Important
The recall centers on the unauthorized sale of various ophthalmic solutions and injections, a serious issue when it comes to patient safety. Market authorization (DIN) ensures the product has undergone strict evaluation for safety, quality, and efficacy in Canada. Without this approval, these products may not meet Canadian regulatory safety standards.
Using non-authorized products could pose potential health risks, including adverse reactions, incorrect dosages, or contamination. People using these recalled medications should act immediately to protect their health and consult their healthcare provider for safe alternatives.
## Details of the Recall
**Products Involved:**
The recalled Aved-branded products include a wide range of ophthalmic solutions and injections. Below is the complete list of affected medications:
- **Atropine Sulfate 0.01% Ophthalmic Solution, 5 mL**
- **Atropine Sulfate 0.02% Ophthalmic Solution, 5 mL**
- **Atropine Sulfate 0.025% Ophthalmic Solution, 5 mL**
- **Atropine Sulfate 0.05% Ophthalmic Solution, 5 mL**
- **Fluorescein Na 0.25% / Proparacaine HCl 0.5% Ophthalmic Solution, 5 mL**
- **Insulin Regular (Human) 25 IU/mL Ophthalmic Solution, 10 mL**
- **Mitomycin 0.04% Ophthalmic Solution (PF), 0.75 mL**
- **Moxifloxacin HCl 150 mcg/0.1 mL Ophthalmic Injection Solution, 0.75 mL**
- **Prednisolone Sodium Phosphate 1% / Moxifloxacin 0.5% / Bromfenac 0.075%**
**Reason for Recall:**
All products were sold without the necessary Canadian market authorization (DIN) due to third-party branding. These branding issues could impact how products are labeled, stored, or regulated.
**Announcement Date:** October 30, 2023
For more information, please refer to the official recall notice [here](https://recalls-rappels.canada.ca/en/alert-recall/aved-products-recall-no-market-authorization).
## What You Should Do
If you use any of the products listed above, follow these steps immediately:
- **Stop Using the Product:** Discontinue use of the affected medication and safely store it out of reach of others.
- **Consult Your Healthcare Professional:** Speak to your doctor or ophthalmologist for guidance on alternative treatments or replacement options.
- **Contact the Manufacturer or Health Canada:** Report any adverse reactions or concerns by contacting Health Canada directly via their website or hotline.
- **Return the Product, If Possible:** Reach out to the retailer or pharmacy where you purchased the medication to inquire about returns or proper disposal methods.
## Stay Safe – Get Instant Recall Alerts
Staying informed about product recalls is essential to remaining safe and protecting your loved ones. Download the *MyRecalls App* today for real-time alerts on recalls, safety notices, and critical updates. With the app, you can:
- Track recalls by category or product name.
- Reduce the risk of using harmful or non-compliant products.
- Receive instant notifications to act promptly.
Your safety can’t wait – [download the MyRecalls App](#) today and stay ahead of potentially harmful products!
For more official details, visit the Canadian recall database [here](https://recalls-rappels.canada.ca/en/alert-recall/aved-products-recall-no-market-authorization).
Stay informed, stay safe!